Patients’ outcome by disease status and MRD before and after blinatumomab. DFS (A) and OS (B) for patients in first CR (CR1), second CR (CR2), or overt relapse (R/R). DFS (C) and OS (D) for CR1/CR2 patients according to pre-blinatumomab MRD and to best MRD response after blinatumomab. Bivariate cox model (E) for DFS and OS with MRD before blinatumomab and after blinatumomab as covariates. MRD⁺ indicates any detectable MRD.